Literature DB >> 22268628

In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.

Hiroshi Yamazaki1, Hiroshi Suemizu, Makiko Shimizu, Sho Igaya, Norio Shibata, Masato Nakamura, Goutam Chowdhury, F Peter Guengerich.   

Abstract

The formation of dihydroxythalidomide and glutathione (GSH) conjugate(s) of 5-hydroxythalidomide was investigated in chimeric mice modified with "humanized" liver: novel humanized TK-NOG mice were prepared by the introduction of thymidine kinase, followed by induction with ganciclovir, and human liver cells were transplanted. Following oral administration of racemic thalidomide (100 mg/kg), plasma concentrations of 5-hydroxy- and dihydroxythalidomide were higher in humanized mice than in controls. After administration of 5-hydroxythalidomide (10 mg/kg), higher concentrations of dihydroxythalidomide were detected. These results indicate that livers of humanized mice mediate thalidomide oxidation, leading to catechol and/or the GSH conjugate in vivo and suggest that thalidomide activation occurs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22268628      PMCID: PMC3976424          DOI: 10.1021/tx300009j

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  16 in total

1.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

2.  Thalidomide revisited: pharmacology and clinical applications.

Authors:  L Calabrese; K Resztak
Journal:  Expert Opin Investig Drugs       Date:  1998-12       Impact factor: 6.206

3.  The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.

Authors:  Masami Hasegawa; Kenji Kawai; Tetsuya Mitsui; Kenji Taniguchi; Makoto Monnai; Masatoshi Wakui; Mamoru Ito; Makoto Suematsu; Gary Peltz; Masato Nakamura; Hiroshi Suemizu
Journal:  Biochem Biophys Res Commun       Date:  2011-01-14       Impact factor: 3.575

4.  The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species.

Authors:  H Schumacher; R L Smith; R T Williams
Journal:  Br J Pharmacol Chemother       Date:  1965-10

5.  Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man.

Authors:  T Eriksson; S Björkman; B Roth; H Björk; P Höglund
Journal:  J Pharm Pharmacol       Date:  1998-12       Impact factor: 3.765

6.  Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients.

Authors:  S K Teo; P J Sabourin; K O'Brien; K A Kook; S D Thomas
Journal:  J Biochem Mol Toxicol       Date:  2000       Impact factor: 3.642

7.  In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Sho Igaya; Makiko Shimizu; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2011-02-07       Impact factor: 3.739

8.  Thalidomide: the tragedy of birth defects and the effective treatment of disease.

Authors:  James H Kim; Anthony R Scialli
Journal:  Toxicol Sci       Date:  2011-04-19       Impact factor: 4.849

9.  Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice.

Authors:  Hiroshi Suemizu; Masami Hasegawa; Kenji Kawai; Kenji Taniguchi; Makoto Monnai; Masatoshi Wakui; Makoto Suematsu; Mamoru Ito; Gary Peltz; Masato Nakamura
Journal:  Biochem Biophys Res Commun       Date:  2008-10-07       Impact factor: 3.575

10.  Thalidomide metabolism by the CYP2C subfamily.

Authors:  Yuichi Ando; Eiichi Fuse; William D Figg
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

View more
  14 in total

1.  In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Norie Murayama; Masahiro Utoh; Norio Shibata; Masato Nakamura; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-03-01       Impact factor: 3.739

Review 2.  P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Authors:  Karl-Dimiter Bissig; Weiguo Han; Mercedes Barzi; Nataliia Kovalchuk; Liang Ding; Xiaoyu Fan; Francis P Pankowicz; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

3.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

4.  Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.

Authors:  Makiko Shimizu; Hiroshi Suemizu; Marina Mitsui; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Xenobiotica       Date:  2016-11-16       Impact factor: 1.908

5.  Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.

Authors:  Norie Murayama; Yasuhiro Kazuki; Daisuke Satoh; Kazuya Arata; Tasuku Harada; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2017       Impact factor: 2.196

6.  Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.

Authors:  Norie Murayama; Hiroshi Suemizu; Shotaro Uehara; Takashi Kusama; Marina Mitsui; Yusuke Kamiya; Makiko Shimizu; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2018       Impact factor: 2.196

7.  The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.

Authors:  Tasaduq H Wani; Anindita Chakrabarty; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich; Goutam Chowdhury
Journal:  Chem Res Toxicol       Date:  2017-08-02       Impact factor: 3.739

8.  Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Authors:  Norie Murayama; Rinie van Beuningen; Hiroshi Suemizu; Christiane Guguen Guillouzo; Norio Shibata; Kanako Yajima; Masahiro Utoh; Makiko Shimizu; Christophe Chesné; Masato Nakamura; F Peter Guengerich; René Houtman; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2014-02-05       Impact factor: 3.739

9.  Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Yasuhiro Kazuki; Ken Oofusa; Shunji Kuribayashi; Makiko Shimizu; Shinichi Ninomiya; Toru Horie; Norio Shibata; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-29       Impact factor: 3.739

Review 10.  Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Marina Mitsui; Makiko Shimizu; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-05       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.